Articles tagged with Rett Syndrome
Two studies in mice reveal that rescuing MeCP2 activity in certain neurons can improve symptoms of Rett syndrome, with different types of neurons playing distinct roles. Researchers are now exploring drugs to improve inhibitory and excitatory neuron balance, offering new hope for potential therapies.
Harvard researchers have identified a disrupted signaling pathway that, when corrected, can ameliorate symptoms of Rett syndrome in mice. The findings may lead to the discovery of compounds or drugs that can benefit children affected by the disease.
Researchers have identified a novel drug target for treating Rett Syndrome and other forms of autism-spectrum disorders. By increasing KCC2 function in diseased nerve cells, the treatment may alleviate symptoms and improve brain development.
The NIH NCATS RDCRN funded 11 sites to study the natural history of Rett syndrome, MECP2 Duplication, CDKL5 disorder, and FOXG1 syndrome. Rettsyndrome.org announces an additional investment of $65,000 to add three more sites, bringing the total to 14, expanding geographical access and clinical infrastructure.
A study published in Nature reveals that MECP2 Duplication Syndrome can be reversed using an antisense oligonucleotide strategy. The therapy, tested on adult mice with the condition, normalized symptoms after four weeks and restored normal brain function.
Rettsyndrome.org has made a financial commitment to support Phase 2 and Phase 3 clinical trials of trofinetide in adult women and children with Rett syndrome. The organization is hopeful that these trials will be successful and lead to the first potential treatments for Rett syndrome.
Researchers have identified a histone deacetylase inhibitor that reverses MECP2 alterations in mutant neurons, offering hope for treating the devastating neurological disorder. The breakthrough uses stem cell-derived 'mini-brains' to screen potential drug libraries, providing an efficient method for finding effective treatments.
The Massachusetts Rett Syndrome Association and Rettsyndrome.org are partnering to support a Phase 2b clinical trial of IGF-1 for the treatment of Rett syndrome. The trial, funded by a $439,000 grant from Rettsyndrome.org, aims to develop new biomarkers and treatments for the condition.
Researchers develop new approach to treating Rett syndrome by extending lifespan and improving behavioral symptoms in mouse models. The treatment targets PTP1B, an enzyme with abnormal levels in the disorder, restoring BDNF signaling and promoting neural growth.
Scientists have discovered a mutated gene, JMJD1C, responsible for cases of unknown origin intellectual disability and autism. The study analyzed the genome of 215 patients with these conditions and found that this gene contributes to Rett syndrome.
Rettsyndrome.org announces new Translational Research Awards to tackle nonsense mutations in MECP2 gene, aiming to develop treatments for Rett syndrome. The awards include the Read-Through Program and Neuro-Habilitation grants, furthering research towards new pharmacologic treatments and improved clinical practices.
Researchers at the University of Iowa found no benefit from bone marrow transplantation in mice models of Rett syndrome, contradicting earlier findings. The study suggests that the initial results were due to factors other than those considered in the new experiment.
Researchers discovered that macrophages play an unexpected role in Rett syndrome, amplifying the disease instead of helping it. The study suggests modulating the immune system could delay symptom onset and slow disease progression.
A two-year clinical trial using low doses of ketamine may hold promise for reversing the devastating symptoms of Rett Syndrome, a neurodevelopmental disorder found almost exclusively in females. The trial aims to measure changes in breathing patterns and overall clinical severity among up to 35 participants.
Researchers found that mutations in MECP2 lead to increased expression of long genes, which are often greater than 100,000 nucleotides in length. This overexpression may be a distinctive signature of Rett Syndrome and related disorders.
Rettsyndrome.org has awarded over $3.1 million in grants to researchers worldwide, focusing on basic, translational, and clinical research for Rett syndrome treatment and therapy development. The organization aims to accelerate research from discovery to medicine, covering a spectrum of Rett syndrome research.
The NIH has awarded a $29 million cooperative agreement to investigate four rare disorders: Rett syndrome, MECP2 Duplications, CDKL5 disorder, and FOXG1 syndrome. The study aims to understand the core clinical features of each disorder and identify factors that can modify their severity.
Researchers found that feeding mice with Rett syndrome a diet supplemented with triheptanoin improved their physical and behavioral symptoms. The oil helped normalize body fat, glucose, and fat metabolism, and increased social interest in other mice. The study offers potential hope for dietary treatment of autism spectrum disorders.
Rettsyndrome.org has awarded $1.5 million to support translational research and launch of the neuro-habilitation therapeutic program, focusing on cognitive therapies, physical therapies, and speech therapies to aid in skill development in Rett syndrome. The grants also fund clinical research to identify effective pharmacologic treatments.
The Rett Syndrome Association of Massachusetts has donated $150,000 to support a Rettsyndrome.org approved grant to Dr. Michela Fagiolini's project at the Boston Children's Hospital. The goal is to assess NMDA receptor modulators for potential treatments in girls diagnosed with Rett syndrome.
A small clinical trial has found that a growth factor known as IGF1 can help treat some symptoms of Rett syndrome, including improved mood, anxiety, and easier breathing. Researchers at Boston Children's Hospital led the trial, which showed no adverse side effects and provided some effectiveness in treating the disease.
Researchers at IDIBELL have discovered that combining effective drugs for Parkinson's disease reduces some Rett syndrome symptoms in mice. This finding offers a potential starting point for studying the effectiveness of similar treatments in humans.
Scientists at the University of Bristol have received funding to test a powerful new drug, NLX-101, which selectively targets serotonin receptors in the brain. The goal is to alleviate the distressing breathing abnormality associated with Rett syndrome, a condition affecting 1 in 10,000 female births worldwide.
A Phase 1 clinical trial of mecasermin (rh-IGF-1) in girls with Rett syndrome demonstrated the treatment's safety and efficacy in ameliorating certain symptoms. The study suggests that IGF-1 could be a potential treatment for Rett Syndrome, paving the way for further research and possible FDA approval.
A panel of 35 genetically characterized DNA samples is now publicly available to help standardize Rett syndrome testing and improve diagnostic accuracy. The collection contains a wide variety of MECP2 mutations associated with most cases of the disorder.
Scientists have redefined the MECP2 protein's role in Rett syndrome, discovering it acts as a global activator rather than repressor. This new understanding can lead to novel therapies for the disease, targeting the AKT/mTOR pathway to reverse symptoms.
A new gene therapy study, published in the Journal of Neuroscience, shows reversal of Rett symptoms in fully symptomatic mice by delivering a healthy MECP2 gene to cells throughout the body and brain. The treatment improved motor function, tremors, seizures, and hand clasping in 65% of cells.
Researchers screened genes for interactions with MECP2 and found five modifiers, including squalene epoxidase, which is drug-targetable. Statin drugs improved symptoms in Rett mice, performing better on mobility tests and living longer. However, further clinical trials are necessary to confirm efficacy and determine optimal treatment.
Two papers reveal key domains of the MECP2 protein responsible for Rett Syndrome, including a methyl binding domain and an NCoR/SMRT Interaction Domain. Understanding these domains is crucial for developing effective treatments.
A study found altered noncoding long chain RNA sequences in Rett Syndrome, which regulates gene expression and neurotransmitter function. The research could lead to new therapeutic strategies targeting lncRNA molecules or GABA receptors.
Key researchers propose standards and guidelines for Rett syndrome research to improve animal study design and transparency. The goal is to shorten the time to effective treatments and accelerate progress towards a cure.
Researchers at Case Western Reserve University School of Medicine have discovered a promising treatment for Rett syndrome by reversing abnormalities in brain activity with an FDA-approved anesthesia drug, ketamine. This study provides new evidence that drug treatment can improve neurological function in individuals with Rett syndrome.
A bone marrow transplant has been shown to arrest severe symptoms of Rett syndrome, a devastating neurological disorder, by replacing faulty immune system cells. The procedure significantly extended the lifespan of Rett mouse models and improved their mobility, breathing, and overall health.
Researchers at OHSU have discovered a critical link between brain-derived neurotrophic factor (BDNF) and Rett syndrome, a neurological disorder affecting one in 10,000 baby girls. The study found that mutant neurons in the brainstem fail to produce BDNF, leading to breathing difficulties and other symptoms.
Researchers found that heart problems in Rett syndrome originate from the loss of the Rett gene (MeCP2) in nerve cells, not heart muscle cells. Abnormalities in brain activity can lead to cardiac malfunctions and death.
Researchers found that glia support neurons and provide energy substrates necessary for function. Re-expression of MeCP2 solely in astrocytes rescues lifespan, breathing, anxiety, and locomotor activities associated with Rett Syndrome in mouse models.
Research by Baylor College of Medicine reveals MeCP2 is required throughout life to maintain healthy brain function. The findings suggest that certain treatments may need to be maintained throughout the lifetime of individuals with Rett Syndrome.
Researchers successfully recreated Rett syndrome in adult mice by 'switching off' a critical disease-causing gene, challenging the notion that early expression of the gene protects against the development of symptoms. The study suggests therapies for Rett syndrome may need to be continuously maintained throughout an individual's life.
Researchers at Baylor College of Medicine have found that neurons need the MeCP2 protein throughout their entire existence. Without it, even as an adult, neurons can develop Rett-like behaviors and die prematurely. This discovery opens up new possibilities for treating Rett syndrome patients by providing a steady supply of the protein.
A new study suggests that Mecp2 is essential for refining synaptic circuits based on sensory experience, leading to the formation of abnormal connections in autism spectrum disorders. This model of Rett syndrome may have implications for other autism-related disorders.
Researchers at Boston Children's Hospital have begun testing mecasermin, a drug that may reverse features of Rett syndrome by enhancing synapse maturation. The three-year pilot study aims to improve neurodevelopment and cardiorespiratory function in girls with the condition.
Researchers found that a mutation in the MeCP2 gene leads to the mobilization of L1 retrotransposons in brain cells, reshuffling their genomes and possibly contributing to the symptoms of Rett syndrome. This discovery sheds light on the complexity of molecular events underlying psychiatric disorders such as autism and schizophrenia.
A team of researchers has developed a human cell-based model of Rett syndrome, overcoming the main limitation of accessing live neurons from patients. The study provides evidence of functional rescue using human cells and opens up new avenues for drug development and high-throughput screening.
Researchers at UCSD School of Medicine created functional neurons from patients with Rett syndrome, providing a new human cellular model for studying autism spectrum disorder. The neurons featured fewer synapses, reduced spine density, and altered calcium signaling, suggesting that synaptic deficiencies may not be permanent.
Researchers found that adult cells from patients with Rett Syndrome could be transformed into induced pluripotent stem cells, which formed functional neurons in cell culture. However, these cells exhibited abnormalities that could be reversed by treating them with drugs, suggesting a potential therapeutic window before disease onset.
Scientists successfully replicated autism in the lab using human induced pluripotent stem (iPS) cells derived from patients with Rett syndrome. The study revealed disease-specific cellular defects, such as reduced functional connections between neurons, which are reversible through insulin-like growth factor 1 (IGF-1) treatment.
A study in mice reveals that loss of the protein MeCP2 in inhibitory nerve cells reproduces nearly all features of Rett syndrome, a devastating neurological disorder. The lack of MeCP2 impairs communication between neurons, leading to cognitive deficits, breathing difficulties, and repetitive behaviors.
Researchers found that removing MECP2 from GABA-producing neurons reduces neurotransmitter production by 30%, reproducing Rett symptoms. The study suggests a possible pathway to understanding neuropsychiatric disorders and potential therapeutic intervention.
Researchers halt life-threatening breathing arrests in mouse models of Rett syndrome using a combination of drugs. The breakthrough offers new hope for treating this devastating disease, which affects 1 in 10,000 young girls.
Researchers at the University of Bristol have discovered a way to prevent intermittent episodes of breath holding associated with Rett syndrome by increasing levels of aminobutyric acid and stimulating serotonin receptors. This breakthrough has significant implications for alleviating symptoms in patients with this debilitating disease.
The International Rett Syndrome Foundation has awarded $1.5 million in research grants to advance understanding of the disorder and develop treatments. These awards will support innovative studies on the genetic and epigenetic mechanisms underlying Rett syndrome.
The 11th Annual Rett syndrome Symposium saw a record turn-out of nearly 150 attendees, including leading scientists, researchers, families affected by the disease, and volunteers. The event featured sessions on treatment strategies and Autism Spectrum Disorders, with new collaborations and relationships forged among participants.
Researchers propose that MeCP2 affects the entire genome in neurons, leading to increased histone acetylation and spurious transcription of 'junk DNA'. This discovery challenges the previous view of MeCP2 as a target-specific transcription factor.
A research collaboration has identified a genetic variation that influences Rett syndrome severity, providing potential new target for treatment. Patients with the normal BDNF genetic variant experienced less severe symptoms, including later onset and fewer seizures.
Researchers found that MeCP2-deficient astrocytes stunt neighboring neuron growth but can recover when exposed to normal glia. This discovery supports the use of glial cells as targets for drug development, potentially leading to new treatments for Rett Syndrome and related MECP2 disorders.
Scientists at Whitehead Institute and MIT's Picower Institute have successfully treated a mouse model of Rett syndrome with daily injections of an active fragment of IGF-1, significantly reducing movement and respiratory irregularities. The treatment promotes nerve cell maturation and increases brain levels of IGF-1.
A molecule that promotes brain development may serve as a possible treatment for Rett syndrome, reversing some of its symptoms in mice. Researchers found that injecting the molecule into mice with faulty brain cells helped them develop normally and reduced symptoms.
The Autism Consortium has published a groundbreaking study defining the mechanism behind Rett syndrome, a neurodevelopmental disorder primarily affecting girls and a leading cause of autism. The research discovered that targeting the IGF1 signaling axis could be a promising therapeutic strategy for treating or reversing Rett Syndrome.
The Rett Syndrome Research Trust aims to bring novel therapeutics addressing the underlying MECP2 pathology to clinical trials within five years. Classic Rett Syndrome affects females almost exclusively, causing severe physical disability and requiring total care.
A study by Baylor College of Medicine researchers reveals a critical function of the MeCP2 protein in regulating neuronal behavior, particularly in relation to stress, aggression, and obesity. The findings demonstrate that MeCP2 is essential for tempering neural responses, enabling appropriate behavior in novel social situations.